Less than 10% of patients that would benefit from weight-loss injections like Wegovy have access to them, states the global health agency as it issues its inaugural guidance on the drugs.
Considering in excess of 1,000,000,000 people worldwide now classified as obese, it is advocating for increased and just access to these injectable treatments.
According to estimates, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.
"Our latest guidelines recognises that obesity is a chronic disease that can be treated with holistic and ongoing support," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are significant obstacles to broad access to the treatments that can help people shift significant weight, explains the body.
Skinny Jab Scarcity
Even in the current most favorable scenario, the production of such drugs would only suffice for around 100 million people – fewer than 10% of eligible patients, per the health organization.
The guideline calls on countries and companies to expand availability, by strategies including licensing agreements.
A patent on a key compound – the core ingredient of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Obesity Drugs Work
These medications mimick a natural hormone to slow digestion, reduce hunger and enhance feelings of fullness so people reduce food intake.
People typically begin shedding pounds in the initial weeks of starting on the regular doses.
Evidence points to patients may regain a significant portion within a year of halting the drug, as their typical hunger resume.
Being above a healthy weight raises your likelihood for developing medical conditions, such as diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight concerns people in all nations and was linked to over three and a half million fatalities worldwide in 2024, according to the WHO.
